HLA-B*5701 and abacavir hypersensitivity

被引：7

作者：

Watson, ME ^{[1
]}

Pimenta, JM

Spreen, WR

Hernandez, JE

机构：

[1] GlaxoSmithKline, Res & Dev, Dept Global Hlth Outcomes, Infect Dis Med Dev Ctr HIV, Res Triangle Pk, NC USA

[2] GlaxoSmithKline, Res & Dev, Dept Epidemiol, Infect Dis Med Dev Ctr HIV, Res Triangle Pk, NC USA

[3] GlaxoSmithKline, Res & Dev, Dept Clin Dev, Infect Dis Med Dev Ctr HIV, Res Triangle Pk, NC USA

来源：

PHARMACOGENETICS | 2004年 / 14卷 / 11期

关键词：

D O I：

10.1097/00008571-200411000-00011

中图分类号：

Q81 [生物工程学（生物技术）]; Q93 [微生物学];

学科分类号：

071005 ; 0836 ; 090102 ; 100705 ;

摘要：

引用

页码：783 / 784

页数：2

共 4 条

[1] The abacavir hypersensitivity reaction: A review [J].

Clay, PG .

CLINICAL THERAPEUTICS, 2002, 24 (10) :1502-1514

[2] Hypersensitivity reactions during therapy with the nucleoside reverse transcriptase inhibitor abacavir [J].

Hetherington, S ;

McGuirk, S ;

Powell, G ;

Cutrell, A ;

Naderer, O ;

Spreen, B ;

Lafon, S ;

Pearce, G ;

Steel, H .

CLINICAL THERAPEUTICS, 2001, 23 (10) :1603-1614

[3] Abacavir hypersensitivity reaction [J].

Hewitt, RG .

CLINICAL INFECTIOUS DISEASES, 2002, 34 (08) :1137-1142

[4] Cost-effectiveness analysis of HLA B*5701 genotyping in preventing abacavir hypersensitivity [J].

Hughes, DA ;

Vilar, FJ ;

Ward, CC ;

Alfirevic, A ;

Park, BK ;

Pirmohamed, M .

PHARMACOGENETICS, 2004, 14 (06) :335-342

← 1 →